The glomerular visceral epithelial cell, or podocyte, is a highly specialized and terminally differentiated cell that is fundamental to the integrity of the glomerular filtration barrier and functions to prevent urinary protein leakage and to oppose intracapillary hydrostatic pressure. Common to many human kidney diseases and experimental animal models is a strong association between podocyte injury and the development of progressive kidney disease. Studies have shown that a decline in podocyte number strongly correlates with, and likely underlies, proteinuria and the progression to glomerulosclerosis. Maintenance of podocyte differentiation, essential to its normal structure and function, is challenged in the setting of glomerular injury, with very divergent outcomes dependent upon the inciting injury. In response to injury, podocytes may undergo several cell fates, including proliferation, de-differentiation, hypertrophy, apoptosis, or necrosis. Common to these potential outcomes of renal injury is their ultimate regulation at the level of the cell cycle. Positive regulators (cyclins and cyclin-dependent kinases) and negative regulators (cyclin-dependent kinase inhibitors) coordinate the cell cycle. There is now a large body of literature confirming the importance of cell cycle regulatory proteins in the cellular response to injury. Emerging lessons from mouse knockout experiments highlight that the cell cycle machinery operates differently in distinct cell types. Recent studies focusing on the roles of cell cycle regulatory proteins specifically in podocytes have provided important clues on how these proteins operate to constrain cell proliferation and preserve differentiation in health, and how they modulate the dysregulated phenotype in diseased states. In disease, both a failure to regenerate lost podocytes and an inappropriate proliferative response can have profound consequences for glomerular structure and function. Here, we will review the latest advances in understanding the roles of cell cycle regulatory proteins in diseases of the podocyte.

Journal Section:
Paper
Keywords:
Cell cycle, Cyclins, CDK inhibitors, Glomerulus, Podocyte, Hypertrophy, Apoptosis, Proliferation, DNA damage
1.
Griffin SV, Pichler R, Dittrich M, Durvasula R, Shankland SJ: Cell cycle control in glomerular disease. Springer Semin Immunopathol 2003;24:441–457.
[PubMed]
https://doi.org/10.1007%2Fs00281-003-0120-8
2.
Shankland SJ, Eitner F, Hudkins KL, Goodpaster T, D’Agati V, Alpers CE: Differential expression of cyclin-dependent kinase inhibitors in human glomerular disease: role in podocyte proliferation and maturation. Kidney Int 2000;58:674–683.
[PubMed]
https://doi.org/10.1046%2Fj.1523-1755.2000.00213.x
3.
Barisoni L, Mokrzycki M, Sablay L, Nagata M, Yamase H, Mundel P: Podocyte cell cycle regulation and proliferation in collapsing glomerulopathies. Kidney Int 2000;58:137–143.
[PubMed]
https://doi.org/10.1046%2Fj.1523-1755.2000.00149.x
4.
Nelson PJ, Sunamoto M, Husain M, Gelman IH: HIV-1 expression induces cyclin D1 expression and pRb phosphorylation in infected podocytes: cell-cycle mechanisms contributing to the proliferative phenotype in HIV-associated nephropathy. BMC Microbiol 2002;2:26.
[PubMed]
https://doi.org/10.1186%2F1471-2180-2-26
5.
Moeller MJ, Soofi A, Hartmann I, Le Hir M, Wiggins R, Kriz W, Holzman LB: Podocytes populate cellular crescents in a murine model of inflammatory glomerulonephritis. J Am Soc Nephrol 2004;15:61–67.
[PubMed]
https://doi.org/10.1097%2F01.ASN.0000102468.37809.C6
6.
Shankland SJ, Floege J, Thomas SE, Nangaku M, Hugo C, Pippin J, Henne K, Hockenberry DM, Johnson RJ, Couser WG: Cyclin kinase inhibitors are increased during experimental membranous nephropathy: potential role in limiting glomerular epithelial cell proliferation in vivo. Kidney Int 1997;52:404–413.
[PubMed]
https://doi.org/10.1038%2Fki.1997.347
7.
Kim YG, Alpers CE, Brugarolas J, Johnson RJ, Couser WG, Shankland SJ: The cyclin kinase inhibitor p21CIP1/WAF1 limits glomerular epithelial cell proliferation in experimental glomerulonephritis. Kidney Int 1999;55:2349–2361.
[PubMed]
https://doi.org/10.1046%2Fj.1523-1755.1999.00504.x
8.
Pippin JW, Durvasula R, Petermann A, Hiromura K, Couser WG, Shankland SJ: DNA damage is a novel response to sublytic complement C5b-9-induced injury in podocytes. J Clin Invest 2003;111:877–885.
[PubMed]
https://doi.org/10.1172%2FJCI200315645
9.
Marshall CB, Pippin JW, Krofft RD, Shankland SJ: Puromycin aminonucleoside induces oxidant-dependent DNA damage in podocytes in vitro and in vivo. Kidney Int 2006;70:1962–1973.
[PubMed]
https://doi.org/10.1038%2Fsj.ki.5001642
10.
Petermann AT, Pippin J, Durvasula R, Pichler R, Hiromura K, Monkawa T, Couser WG, Shankland SJ: Mechanical stretch induces podocyte hypertrophy in vitro. Kidney Int 2005;67:157–166.
[PubMed]
https://doi.org/10.1111%2Fj.1523-1755.2005.00066.x
11.
Hoshi S, Shu Y, Yoshida F, Inagaki T, Sonoda J, Watanabe T, Nomoto K, Nagata M: Podocyte injury promotes progressive nephropathy in Zucker diabetic fatty rats. Lab Invest 2002;82:25–35.
[PubMed]
https://doi.org/10.1038%2Flabinvest.3780392
12.
Kuan CJ, al-Douahji M, Shankland SJ: The cyclin kinase inhibitor p21WAF1, CIP1 is increased in experimental diabetic nephropathy: potential role in glomerular hypertrophy. J Am Soc Nephrol 1998;9:986–993.
[PubMed]
13.
Awazu M, Omori S, Ishikura K, Hida M, Fujita H: The lack of cyclin kinase inhibitor p27(Kip1) ameliorates progression of diabetic nephropathy. J Am Soc Nephrol 2003;14:699–708.
[PubMed]
https://doi.org/10.1097%2F01.ASN.0000051726.41601.C0
14.
Baba M, Wada J, Eguchi J, Hashimoto I, Okada T, Yasuhara A, Shikata K, Kanwar YS, Makino H: Galectin-9 inhibits glomerular hypertrophy in db/db diabetic mice via cell-cycle-dependent mechanisms. J Am Soc Nephrol 2005;16:3222–3234.
[PubMed]
https://doi.org/10.1681%2FASN.2004110915
15.
Xu ZG, Yoo TH, Ryu DR, Cheon Park H, Ha SK, Han DS, Adler SG, Natarajan R, Kang SW: Angiotensin II receptor blocker inhibits p27Kip1 expression in glucose-stimulated podocytes and in diabetic glomeruli. Kidney Int 2005;67:944–952.
[PubMed]
https://doi.org/10.1111%2Fj.1523-1755.2005.00158.x
16.
Wada T, Pippin JW, Terada Y, Shankland SJ: The cyclin-dependent kinase inhibitor p21 is required for TGF-beta1-induced podocyte apoptosis. Kidney Int 2005;68:1618–1629.
[PubMed]
https://doi.org/10.1111%2Fj.1523-1755.2005.00574.x
17.
Wada T, Pippin JW, Marshall CB, Griffin SV, Shankland SJ: Dexamethasone prevents podocyte apoptosis induced by puromycin aminonucleoside: role of p53 and Bcl-2-related family proteins. J Am Soc Nephrol 2005;16:2615–2625.
[PubMed]
https://doi.org/10.1681%2FASN.2005020142
18.
Xing CY, Saleem MA, Coward RJ, Ni L, Witherden IR, Mathieson PW: Direct effects of dexamethasone on human podocytes. Kidney Int 2006;70:1038–1045.
[PubMed]
https://doi.org/10.1038%2Fsj.ki.5001655
19.
Griffin SV, Olivier JP, Pippin JW, Roberts JM, Shankland SJ: Cyclin I protects podocytes from apoptosis. J Biol Chem 2006;281:28048–28057.
[PubMed]
https://doi.org/10.1074%2Fjbc.M513336200
20.
Griffin SV, Hiromura K, Pippin J, Petermann AT, Blonski MJ, Krofft R, Takahashi S, Kulkarni AB, Shankland SJ: Cyclin-dependent kinase 5 is a regulator of podocyte differentiation, proliferation, and morphology. Am J Pathol 2004;165:1175–1185.
[PubMed]
© 2007 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2007
You do not currently have access to this content.